文献检索

查找使用阿拉丁产品的科研文献

检索与阿拉丁产品相关的同行评审论文、DOI、PubMed 编号、期刊、作者、CAS 号及研究领域。

科研影响力快照

与阿拉丁产品相关的已发表科研成果

在搜索之前,这些指标可帮助访客快速了解产品关联科研的规模与质量。

346,364+ SCI 论文 与阿拉丁产品引用相关
2,295,288.15 总影响因子 匹配文献记录中影响因子的总和
81.20 最高期刊影响因子 匹配期刊中的最高 IF
6.63 平均期刊影响因子 匹配文献的平均 IF

参考指标 指标基于阿拉丁文献引用数据库及期刊影响因子记录。文献关联仅供科研参考,请以原始文献为准。

热门产品

视图 列表 网格

4 项

设置提升方向
肠道Fxr
Food Bioscience · 2025 · IF 5.9

Dose-specific amelioration of caffeic acid phenethyl ester on high-fat diet-induced obesity based on intestinal FXR signaling and bile acid regulation

Haiying Cai,Menghui Lin,Kaiyi Chen,Yuanfeng Wu,Thanh Ninh Le,Junhui Zhang,Minjie Zhao

The circulating bile acids (BAs) play critical roles in regulating the glycolipid metabolism, inflammation, and other physiological functions. Male C57BL/6J mice were given high-fat diet (HFD) with 500 mg/kg and 2500 mg/kg caffeic acid phenethyl ester (CAPE) for 16 weeks (CAPE500 and CAPE2500). The results showed that both the two dose of CAPE treatment improved the glycolipid metabolism and inflammation in HFD-induced obese mice. The BA profile analysis revealed that CAPE2500 increased hepatic and serum circulating BA levels compared to HFD ( P- value of 0.347 and 0.467, respectively), while CAPE500 showed decreased serum circulating BA levels compare to CAPE2500 ( P- value of 0.0881), suggesting dose-specific ameliorative mechanisms of CAPE on obesity based on BA signaling. Further study found significantly lower bile salt hydrolase (BSH) activity in the ileal contents of the CAPE500 group compared to the HFD group, which resulted in suppressed intestinal FXR signaling and improved glycolipid metabolism through inhibiting ileal FXR-enhanced ceremide synthesis. However, CAPE2500 increased serum circulating BA levels by significantly decreasing BA excretion compared with the HFD and CAPE500 groups ( P < 0.0001 and P < 0.01, respectively), enhancing brown adipose tissue thermogenesis by activating the TGR5/UCP-1 signaling axis. Furthermore, CAPE also ameliorated the gut microbiota disorders and obesity induced by HFD. This study reveals a dose-specific effect of CAPE treatment on circulating BA content, ileal BSH-FXR signaling and gut microbiota, which improves glucose and lipid dyshomeostasis through different mechanisms.

CAS / MDL: 104594-70-9
研究领域: 营养学 · 分子生物学 · 微生物学
✓ 已验证 产品关联 DOI 高影响因子
查看原文 查看 PubMed
Food Bioscience · 2024 · IF 4.8

Dietary chromium chemical species mitigate inflammation and cholestasis in primary sclerosing cholangitis via regulating bile acid metabolism

Yu Shen,Baorong Jiang,Zejia Hao,Chenchen Zhang,Zhan Zhang,Qian Wu,Lei Li,Ping Jiang

Both chromium picolinate (Cr-pic) and chromium trichloride (CrCl 3 ) were used as dietary supplements in agricultural products and foodstuffs. We found either these two forms of Cr(III) could ameliorate inflammation and cholestasis in DDC-induced primary sclerosing cholangitis (PSC) mice via regulating bile acid metabolism. Although two Cr(III) are able to alleviate hepatic inflammation by reducing the aggregation of macrophage, Cr-pic exhibiting superior efficacy in decreasing M1 macrophages. Two Cr(III) show inconsistent in regulating intestinal Fxr , but Cr-pic could active intestinal Fxr , promoting intestinal barrier repair. Additionally, both Cr-pic and CrCl 3 enhanced functional abundance of BSH enzymes involved in bile acid transformation, with Cr-pic seems to perturb the abundance of genus more than CrCl 3. In conclusion, this study highlights the efficacy of Cr-pic and CrCl 3 in mitigating inflammation and cholestasis in PSC, Cr-pic is expected superior than CrCl 3 to be supplement ingredient used in PSC treatment via regulating bile acid metabolism.

CAS / MDL: 10060-12-5
研究领域: 营养学 · 胃肠病学 · 药理学
✓ 已验证 产品关联 DOI 高影响因子
查看原文 查看 PubMed
Journal of Functional Foods · 2024 · IF 3.8

Lonicerin attenuates high-fat diet-induced hepatic steatosis through modulation of the gut microbiota-bile acid-FXR axis in mice

Shuang Wang,Chunyue Zhao,Xueran Huang,Yongfen Gao,Yang Qiu,Rui Jiao,Hanyue Zhu,Huafang Ding,Rui Lin,Zouyan He

Lonicera japonica Thunb. is widely used in Asian countries as a food ingredient to make healthy drinks, with lonicerin, a flavone O -glycoside, as a predominant bioactive compound. This study investigated lonicerin’s effects on high-fat diet-induced hepatic steatosis in mice, compared to its aglycone luteolin. Results showed that lonicerin significantly reduced diet-induced body weight gain and hepatic lipid accumulation in mice, demonstrating greater efficacy than luteolin. This lipid-lowering effect was due to inhibited hepatic fatty acid (FA) biosynthesis and promoted fecal lipid excretion. Moreover, lonicerin favorably modulated gut microbiota by increasing Dubosiella , Eubacterium_brachy_group , and Bilophila , while reducing the pathogenic Desulfovibrionaceae . These changes led to elevated short-chain fatty acid production and altered fecal bile acid (BA) profiles, likely activating the intestinal FXR-FGF15 pathway to inhibit hepatic FA synthesis. In conclusion, lonicerin alleviated diet-induced hepatic steatosis by promoting fecal lipid excretion and inhibiting hepatic FA biosynthesis through modulating the gut microbiota-BA-intestinal FXR axis.

CAS / MDL: 79902-63-9
研究领域: 药理学 · 胃肠病学 · 营养学 · 微生物学
✓ 已验证 产品关联 DOI 高影响因子
查看原文 查看 PubMed
Food Science and Human Wellness · 2024 · IF 5.6

Saikosaponin D improves non-alcoholic fatty liver disease via gut microbiota-bile acid metabolism pathway

Lan Li,Shengye Yang,Xinyu Liang,Yameng Liu,Hualing Xu,Xiaozhen Guo,Cen Xie,Xiaojun Xu

Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease worldwide. Bupleurum is widely used in the treatment of non-alcoholic fatty liver, and saikosaponin D (SSD) is one of the main active components of Bupleurum. The purpose of this study was to investigate the efficacy of SSD in the treatment of NAFLD and to explore the mechanism of SSD in the improvement of NAFLD based on “gut-liver axis”. Our results showed that SSD dose-dependently alleviated high fat diet-induced weight gain in mice, improved insulin sensitivity, and also reduced liver lipid accumulation and injury-related biomarkers aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Further exploration found that SSD inhibited the mRNA expression levels of farnesoid X receptor ( Fxr ), small heterodimer partner ( Shp ), recombinant fibroblast growth factor 15 ( Fgf15 ) and apical sodium dependent bile acid transporter ( Asbt ) in the intestine, suggesting that SSD improved liver lipid metabolism by inhibiting intestinal FXR signaling. SSD can significantly reduce the gut microbiota associated with bile salt hydrolase (BSH) expression, such as Clostridium . Decreased BSH expression reduced the ratio of unconjugated to conjugated bile acids, thereby inhibiting the intestinal FXR. These data demonstrated that SSD ameliorated NAFLD potentially through the gut microbiota-bile acid-intestinal FXR pathway and suggested that SSD is a promising therapeutic agent for the treatment of NAFLD.

CAS / MDL: 7727-54-0
研究领域: 药理学 · 胃肠病学 · 微生物学 · 代谢学 · 分子生物学
✓ 已验证 产品关联 DOI 高影响因子
查看原文 查看 PubMed
已复制

文献关联基于可获得的产品、CAS、DOI 及引用记录。收录不代表作者或出版方对阿拉丁产品的背书,请以原始文献为准。